DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024" report to their offering.
The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024.
The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.
Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.
Some major players of the epilepsy drugs market include:
- Johnson & Johnson
- UCB Pharma, Inc.
- Abbott Laboratories, Inc.
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Novartis AG
- Sanofi Aventis S.A.
- Shire PLC
- Tansna Therapeutics, Inc.
Key Topics Covered:
1 Executive Summary
2 Market Snapshot
3 Market Variables, Trends & Scope
4 Market Categorization 1: Epilepsy Drugs Estimates & Trend Analysis
5 Market Categorization 3: Regional Estimates & Trend Analysis, by Drug
6 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/vs7lbp/epilepsy_drugs